Lexaria Bioscience (LEXX) EBIT (2017 - 2026)

Lexaria Bioscience has disclosed EBIT across 10 years of filings, most recently posting -$1.5 million for Q1 2026.

• EBIT for Q1 2026 came in at -$1.5 million, up 47.22% year-over-year; the trailing twelve-month figure through Feb 2026 was -$9.5 million (down 0.82% YoY), and the FY2025 annual result was -$11.9 million, down 106.51% from the prior year.
• EBIT came in at -$1.5 million for Q1 2026 at Lexaria Bioscience, up from -$1.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$668005.0 in Q1 2024 to a low of -$3.8 million in Q2 2025.
• The 5-year median for EBIT is -$1.7 million (2022), against an average of -$1.9 million.
• Across the five-year window, EBIT surged 49.53% in 2024 and tumbled 311.83% in 2025, its largest moves.
• Lexaria Bioscience's EBIT stood at -$1.7 million in 2022, then surged by 32.81% to -$1.1 million in 2023, then tumbled by 136.2% to -$2.7 million in 2024, then soared by 41.52% to -$1.6 million in 2025, then climbed by 7.74% to -$1.5 million in 2026.
• The last three EBIT figures came in at -$1.5 million (Q1 2026), -$1.6 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.